Depreciation of Inhibikase Therapeutics, Inc. from 31 Dec 2021 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Summary
Inhibikase Therapeutics, Inc. quarterly and annual Depreciation in USD history and change rate from 31 Dec 2021 to 30 Sep 2025.
  • Inhibikase Therapeutics, Inc. Depreciation for the quarter ending 30 Sep 2025 was $23,688, a 261% increase year-over-year.
  • Inhibikase Therapeutics, Inc. Depreciation for the twelve months ending 30 Sep 2025 was $67,066, a 155% increase year-over-year.
  • Inhibikase Therapeutics, Inc. annual Depreciation for 2024 was $26,272, a 85% decline from 2023.
  • Inhibikase Therapeutics, Inc. annual Depreciation for 2023 was $177,398, a 2539% increase from 2022.
  • Inhibikase Therapeutics, Inc. annual Depreciation for 2022 was $6,723.
Source SEC data
View on sec.gov
Depreciation, Trailing 12 Months (USD)
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Change (%)
Depreciation, Annual (USD)
Depreciation, YoY Annual Change (%)

Inhibikase Therapeutics, Inc. Quarterly Depreciation (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $67,066 $23,688 +$17,120 +261% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025 2025 Q3
Q2 2025 $49,946 $24,157 +$17,588 +268% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $32,358 $12,654 +$6,086 +93% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $26,272 $6,567 -$16 -0.24% 01 Oct 2024 31 Dec 2024 10-Q 14 May 2025 2025 Q1
Q3 2024 $26,288 $6,568 $0 0% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025 2025 Q3
Q2 2024 $26,288 $6,569 -$152,635 -96% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q1 2024 $178,923 $6,568 +$1,525 +30% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2023 $177,398 $6,583 +$1,541 +31% 01 Oct 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
Q3 2023 $175,857 $6,568 +$4,887 +291% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $170,970 $159,204 +$159,204 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024 2024 Q2
Q1 2023 $11,766 $5,043 +$5,043 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q4 2022 $6,723 $5,042 01 Oct 2022 31 Dec 2022 10-K 27 Mar 2024 2023 FY
Q3 2022 $1,681 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $0 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $0 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1

Inhibikase Therapeutics, Inc. Annual Depreciation (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $26,272 -$151,126 -85% 01 Jan 2024 31 Dec 2024 10-Q 14 May 2025 2025 Q1
2023 $177,398 +$170,675 +2539% 01 Jan 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
2022 $6,723 +$6,723 01 Jan 2022 31 Dec 2022 10-K 27 Mar 2024 2023 FY
2021 $0 01 Jan 2021 31 Dec 2021 10-K 31 Mar 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.